These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28520704)

  • 1. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.
    Zhang Y; Wu S; Xia Y; Wang N; Zhou L; Wang J; Fang R; Sun F; Chen M; Zhan S
    Med Sci Monit; 2017 May; 23():2348-2356. PubMed ID: 28520704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
    Xu C; Pang Y; Li R; Ruan Y; Wang L; Chen M; Zhang H
    J Infect; 2018 Apr; 76(4):348-353. PubMed ID: 29374587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
    Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
    Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study.
    Merid MW; Gezie LD; Kassa GM; Muluneh AG; Akalu TY; Yenit MK
    BMC Infect Dis; 2019 Mar; 19(1):286. PubMed ID: 30917788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
    Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
    PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
    Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
    Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence and risk factors on the resistance related to second-line drugs among multi-drug resistant tuberculosis cases in Shanghai, China].
    Li J; Zhang YY; Gui XH; Yuan ZA; Pan QC; Mei J; Shen X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):796-8. PubMed ID: 22967331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study.
    Lecai J; Mijiti P; Chuangyue H; Qian G; Weiguo T; Jihong C
    Front Public Health; 2023; 11():1134938. PubMed ID: 37408751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and Clinical Characteristics of Pediatric Drug-Resistant Tuberculosis in Chongqing, China.
    Guo Q; Pan Y; Yang Z; Liu R; Xing L; Peng Z; Zhu C
    PLoS One; 2016; 11(3):e0151303. PubMed ID: 26959480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.
    Sun Y; Harley D; Vally H; Sleigh A
    PLoS One; 2017; 12(1):e0168865. PubMed ID: 28118372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.